March 9 (Reuters) – International drugmakers are ramping up U.S. manufacturing and stockpiling stock because the Trump administration considers a 100% tariff on imported branded and patented medicines.
Though enforcement is delayed for corporations investing in U.S. manufacturing, the coverage has already prompted fast-tracked tasks, value cuts and direct-to-consumer gross sales.
Pfizer and AstraZeneca secured multi-year tariff exemptions via pricing offers and commitments to the brand new TrumpRx.gov platform. Eli Lilly, Johnson & Johnson and Merck have pledged billions to broaden U.S. operations to keep away from penalties.
This is what drugmakers are doing to mitigate supply-chain dangers and reassure buyers:
Pfizer
Pfizer reached a take care of President Donald Trump on September 30 to speculate $70 billion in analysis and growth and home manufacturing, and obtained a three-year grace interval exempting its merchandise from the pharmaceutical-targeted tariffs.
GSK
The London-based drugmaker plans to speculate $30 billion in U.S. analysis and growth and provide chain infrastructure over 5 years.
Eli Lilly
U.S. President Donald Trump mentioned in January that Eli Lilly plans to construct six vegetation in america.
Lilly mentioned final 12 months that it deliberate to spend a minimum of $27 billion to construct 4 U.S. vegetation to broaden manufacturing and bolster medical provide chains. The corporate has since introduced particulars on three vegetation, in Alabama, Virginia and Texas.
Lilly in January mentioned it should construct a $3.5 billion pharmaceutical manufacturing facility in Pennsylvania, its fourth new website, in an effort to broaden U.S. manufacturing and bolster medical provide chains.
Johnson & Johnson
The drugmaker plans to lift U.S. investments by 25%, totaling $55 billion, over the following 4 years. It plans to construct 4 vegetation, together with one at Wilson, North Carolina, and one other at Tokyo-based Fujifilm Biotechnologies’ manufacturing website in Holly Springs, North Carolina, over the following 10 years.
The corporate mentioned in February it might make investments greater than $1 billion to construct a brand new cell remedy facility in Pennsylvania, a part of its bigger plans introduced final 12 months to scale up U.S. manufacturing.
Roche
The Swiss drugmaker mentioned in April final 12 months it might make investments $50 billion within the U.S. over the following 5 years.
A month later, it introduced an extra $550 million funding to broaden its Indianapolis diagnostics manufacturing hub. The growth will span Indiana, Pennsylvania, Massachusetts, and California, creating greater than 12,000 jobs.
In January, Roche mentioned it should greater than double its funding in its drug manufacturing facility in Holly Springs, North Carolina, to about $2 billion, up from the over $700 million introduced in Might 2025.
AstraZeneca
The Anglo-Swedish drugmaker will make investments $50 billion on U.S. manufacturing by 2030. The funding will fund a brand new drug substance facility in Virginia, its largest single-site world funding, alongside expansions in Maryland, Massachusetts, California, Indiana and Texas.
It has already began expertise transfers and is managing stock in 2025 to attenuate any tariff hit. Firm executives have mentioned the impression can be “very short-lived.”
Novartis
The Swiss drugmaker plans to spend $23 billion to construct and broaden 10 services within the U.S. over the following 5 years. This consists of constructing six new manufacturing vegetation and increasing its San Diego analysis and growth website, which is anticipated to create greater than 1,000 jobs.
Sanofi
The French drugmaker plans to speculate a minimum of $20 billion within the U.S. via 2030 to spice up manufacturing and analysis. Sanofi plans to broaden its U.S. manufacturing capability via direct investments within the firm’s websites and partnerships with different home producers.
Chief Monetary Officer François Roger mentioned in July the potential tariffs are anticipated to have a restricted impression in 2025, as the corporate already has stock in place within the U.S.
Biogen
The U.S. drugmaker will make investments $2 billion extra in its current manufacturing vegetation in North Carolina, including capability for gene-targeting therapies and automation. The corporate has seven factories within the state, with an eighth set to start operations in late 2025.
Merck
The U.S. drugmaker has begun constructing a $3 billion pharmaceutical manufacturing plant in Virginia as a part of its over $70 billion funding to broaden home manufacturing and analysis and growth.
It would additionally make investments $1 billion in a brand new Delaware plant to make biologics and most cancers drug Keytruda, to spice up U.S. manufacturing and probably create over 4,500 jobs. It additionally opened a $1 billion facility at its North Carolina website in March.
Merck’s animal well being unit will make investments $895 million to broaden its Kansas manufacturing and R&D website, a part of a broader $9 billion U.S. funding via 2028.
CEO Robert Davis in July flagged minimal impression from potential tariffs in 2025, and that the corporate remained well-positioned because of stock administration and transferring of producing to the U.S.
Amgen
The U.S.-based biopharma agency plans to speculate $900 million to broaden its Ohio manufacturing facility, bringing complete funding within the state to $1.4 billion and including 750 jobs. In December, the corporate dedicated $1 billion to construct a second facility in Holly Springs, North Carolina.
Amgen mentioned in September it’s investing greater than $600 million to construct a brand new analysis and growth middle at its headquarters in Thousand Oaks, California.
The drugmaker introduced it should make investments $650 million to broaden drug manufacturing at its facility in Juncos, Puerto Rico, a transfer anticipated to create almost 750 jobs.
Novo Nordisk
The Danish pharmaceutical firm mentioned in August its robust U.S. manufacturing footprint positions it properly for tariff challenges, describing itself as “very U.S.-centric and U.S.-focused”.
AbbVie
U.S. drugmaker AbbVie mentioned in January it has dedicated $100 billion over the following decade to U.S.-based analysis and growth as a part of its three-year take care of the Trump administration to cut back drug costs.
It has 11 manufacturing websites within the U.S. and has mentioned it’s “pretty insulated” from any tariff impression this 12 months, given stock administration actions.
The corporate mentioned in February that it plans to speculate $380 million to construct two manufacturing services at its present North Chicago, Illinois, campus, to help the manufacturing of its neuroscience and weight problems drugs.
Gilead Sciences
Earlier this 12 months, the drugmaker introduced $11 billion in new deliberate funding within the U.S. so as to add to its home manufacturing and analysis heft, taking its complete pledged funding to $32 billion.
Gilead mentioned in September that it began work on a pharmaceutical growth and manufacturing hub at its headquarters in Foster Metropolis, California, along with which, it’s at the moment growing two different websites.
Cipla
The Indian drugmaker is increasing its U.S. manufacturing footprint by investing in capability growth for complicated respiratory merchandise at its superior services in Fall River, Massachusetts, and Central Islip, New York.
CSL
Australia’s CSL mentioned in November it might make investments $1.5 billion within the U.S. to fabricate plasma-derived therapies, increasing its footprint within the nation over the following 5 years.
In March, the corporate introduced the growth of its plasma remedy manufacturing facility in Kankakee, Illinois, which is anticipated to be operational by 2031.
(Reporting by Siddhi Mahatole, Kamal Choudhury, Puyaan Singh, Sneha S Okay and Sahil Pandey in Bengaluru; Modifying by Tasim Zahid, Sahal Muhammed, Shinjini Ganguli and Maju Samuel)
